Inozyme Pharma Inc reports results for the quarter ended in June - Earnings Summary

Inozyme Pharma

15/08/2022 15:08

* Inozyme Pharma Inc  INZY.OQ  reported a quarterly adjusted
loss
of 38 cents​​ per share for the quarter ended in June. The mean
expectation of seven analysts for the quarter was for a loss
of 48 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Inozyme Pharma Inc's reported EPS for the quarter was a
loss
of 38 cents​.
    * The mean earnings estimate of analysts had risen by
about 10.8%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Inozyme Pharma Inc shares had fallen by 27.0% this
quarter and
lost 49.0% so far this year.
    * The company reported a quarterly loss of $15.26 million.
    * Wall Street's median 12-month price target for Inozyme
Pharma
Inc is $20.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 15
at 02:08 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.48          -0.38          Beat
 Mar. 31 2022      -0.82          -0.71          Beat
 Dec. 31 2021      -0.68          -0.79          Missed
 Sep. 30 2021      -0.61          -0.60          Beat